

The ACROSS-China trial

Submission date 05/01/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 29/05/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 29/05/2008	Condition category Circulatory System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Yongjun Wang

Contact details

Beijing Tiantan Hospital
Tiantan Xili 6
Chongwen District
Beijing
China
100050

Additional identifiers

Protocol serial number

ACROSS-protocol 5

Study information

Scientific Title

Abnormal gluCOse Regulation in patients with acute strOke acroSS China: a national multicentre prospective study

Acronym

ACROSS-China

Study objectives

1. The prevalence of abnormal glucose regulation in patients with acute stroke is high
2. The distribution of stroke subtypes is different in the subtypes of the abnormal glucose regulation
3. Patients with or without abnormal glucose regulation will have different outcomes and recurrent risk of stroke
4. Different subtypes of abnormal glucose regulation have different effects on the outcomes and recurrence of stroke

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Tiantan Hospital Ethics Committee on the 28th August 2007

Study design

Multicentre observational, prospective, cohort study

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Abnormal glucose regulation, acute stroke

Interventions

All participants without a history of diabetes mellitus will be identified as having abnormal glucose regulation or not by using the oral glucose tolerance test (OGTT) three days before discharge. The outcome and recurrence of stroke will be compared between the patients with and without abnormal glucose regulation respectively at three months and one year after the onset of stroke as below:

1. Modified Rankin Scale (mRS)
2. The times of stroke recurrence

The current therapy measures of abnormal glucose regulation in patients with acute stroke will be observed during in-hospital and follow-up.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

The prevalence of abnormal glucose regulation after acute stroke in China, measured by OGTT before discharge.

Key secondary outcome(s)

1. The distribution of stroke subtypes is different in the subtypes of the abnormal glucose regulation
2. The outcome and recurrence risk of stroke in patients with or without abnormal glucose regulation

Completion date

01/09/2008

Eligibility

Key inclusion criteria

1. Older than 18, either sex
2. Acute stroke: diagnosed on World Health Organization (WHO) criteria
3. Acute primary stroke patients within 14 days

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Cerebral infarction without symptoms and signs
2. Non-cerebrovascular events
3. Stroke patients out of 14 days
4. Without the content of patients or their legal agents

Date of first enrolment

01/01/2008

Date of final enrolment

01/09/2008

Locations

Countries of recruitment

China

Study participating centre
Beijing Tiantan Hospital
Beijing
China
100050

Sponsor information

Organisation
Bayer (China) Limited

ROR
<https://ror.org/05d5yxq17>

Funder(s)

Funder type
Industry

Funder Name
Bayer (China) Limited

Funder Name
11th Five-year National Supporting Schedule of Science and Technology (China)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration